Is it time to retire efavirenz as a first-line option worldwide?

Juan V. Guanira
, Carl J. Fichtenbaum

Investigaciones Médicas en Salud (INMENSA)
University of Cincinnati College of Medicine

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	317-318
Number of pages	2
Journal	AIDS
Volume	36
Issue number	2
DOIs	https://doi.org/10.1097/QAD.0000000000003101
State	Published - 1 Feb 2022
Externally published	Yes

Access to Document

10.1097/QAD.0000000000003101

Other files and links

Link to publication in Scopus

Cite this

@article{d0d7053eb0ff450ebdabbcefe68c5025,

title = "Is it time to retire efavirenz as a first-line option worldwide?",

author = "Guanira, \{Juan V.\} and Fichtenbaum, \{Carl J.\}",

year = "2022",

month = feb,

day = "1",

doi = "10.1097/QAD.0000000000003101",

language = "Ingl{\'e}s",

volume = "36",

pages = "317--318",

journal = "AIDS",

issn = "0269-9370",

number = "2",

}

TY - JOUR

T1 - Is it time to retire efavirenz as a first-line option worldwide?

AU - Guanira, Juan V.

AU - Fichtenbaum, Carl J.

PY - 2022/2/1

Y1 - 2022/2/1

UR - https://www.scopus.com/pages/publications/85122299624

U2 - 10.1097/QAD.0000000000003101

DO - 10.1097/QAD.0000000000003101

M3 - Comentario/Debate

C2 - 34934022

AN - SCOPUS:85122299624

SN - 0269-9370

VL - 36

SP - 317

EP - 318

JO - AIDS

JF - AIDS

IS - 2

ER -